Neutral
Argenx SE is gaining investor attention following updates on the commercial rollout of its autoimmune therapy Vyvgart and its broader antibody pipelin...
Neutral
Argenx SE remains in focus following its latest quarterly results, with particular attention on the growth of its lead therapy, Vyvgart, for generaliz...
Neutral
argenx (Euronext & Nasdaq: ARGX) announced it will host a conference call and audio webcast on Thursday, May 7, 2026, at 2:30 PM CET (8:30 AM ET) to d...
Neutral
argenx (Euronext & Nasdaq: ARGX) announced it will host a conference call and audio webcast on May 7, 2026, at 2:30 PM CET / 8:30 AM ET to discuss its...